After the results observed in several clinical trials [2,3,4,5], ICIs, including anti-programmed death receptor-1 (PD-1), anti-programmed death ligand-1 (PD-L1) and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies, have become a standard of care in first-line treatment of non-oncogene-addicted metastatic NSCLC as a monotherapy or in combination with platinum-based chemotherapy, according to PD-L1 status [6,7,8,9,10,11]. Here, CTLA4 is linked to non-small cell lung carcinoma.